Macrolides in the treatment of asthma and cystic fibrosis.
Asthma and cystic fibrosis are two respiratory diseases characterized by chronic inflammation, leading to remodelling of the airways. Macrolides are widely used antibiotics, with a peculiar anti-inflammatory effect. On the basis of the methodologies used by the Cochrane collaboration, this review discusses the evidence for their long-term use as anti-inflammatory agents in these two diseases. Three randomized-controlled trials (RCTs) were identified for both asthma and cystic fibrosis. A positive effect of macrolides on reducing eosinophil numbers and markers of eosinophilic inflammation was demonstrated in patients with asthma. Data on cystic fibrosis demonstrated an effect on lung function with an increase of 5.4% in forced vital capacity (FVC) in patients treated with macrolide vs. placebo, but without a significant effect on FEV1. Side-effects were rare, mild and reversible on withdrawal of treatment. Although preliminary data from small studies are promising, the role of macrolides in the treatment of these chronic disorders needs to be more firmly established with larger, well-designed trials, targeted to investigate major clinical outcomes.
Ferrara
G
G
Department of Oncology and Hematology, Section of Respiratory Diseases, University of Modena and Reggio Emilia, Modena, Italy.
Losi
M
M
Franco
F
F
Corbetta
L
L
Fabbri
L M
LM
Richeldi
L
L
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D003550:Cystic Fibrosis / Q000188:drug therapy*; D004334:Drug Administration Schedule; D019317:Evidence-Based Medicine; D006801:Humans; D018942:Macrolides / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
D000894:Anti-Inflammatory Agents, Non-Steroidal; D018942:Macrolides